Abbott Laboratories (BCBA:ABT)

Market Cap	274.56T +20.9%
Revenue (ttm)	64.34T +5.7%
Net Income	9.47T -51.3%
EPS	5,399.21 -51.3%
Shares Out	n/a
PE Ratio	29.00
Forward PE	19.66
Dividend	583.94 (1.43%)
Ex-Dividend Date	Jan 15, 2026

Volume	3,491
Average Volume	3,593
Open	40,940
Previous Close	40,860
Day's Range	40,800 - 41,540
52-Week Range	35,950 - 53,525
Beta	n/a
RSI	31.92
Earnings Date	Jan 22, 2026

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1888
• Employees: 115,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABT

Financial Performance

In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.52 billion, a decrease of -51.13%.

Financial numbers in USD